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Holocarboxylase synthetase (HCS) is a chromatin protein that is essential for
mediating the covalent binding of biotin to histones. Biotinylation of histones plays
crucial roles in the repression of genes and repeats in the human genome. The objective
of this project was to determine genomic binding sites of holocarboxylase synthetase
(HCS) in the human chromatin of breast cell lines using an antibody independent
technology. We tested the feasibility of DNA adenine methyltransferase identification
(DamID) technology to map HCS binding sites in human mammary cell lines. Full-length
HCS was fused to Dam for subsequent transfection into breast cancer (MCF-7) and
normal breast (MCF-10A) cells. HCS docking sites in chromatin were identified by using
the unique adenine methylation sites established by Dam in the fusion construct; docking
sites were unambiguously identified using methylation sensitive digestion, cloning, and
sequencing. Fifteen novel HCS binding sites were identified and included sequences
within genes coding for inositol polyphosphate-5-phosphatase A, corticotropin hormone
precursor, myosin heavy chain 9 non-muscle, cadherins 8 and 11, prolactin, leptin
precursor, schwannomin 1, apoptosis inhibitor, netrin-G1 ligand, neuron navigator, SRYbox4, purinergic receptor, and CUB and sushi domains. We conclude that DamID is a
useful technology to map HCS binding sites in human chromatin and propose that the

entire set of HCS binding sites could be mapped by combining DamID with microarray
technology.
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Chapter 1

1.1 Introduction

The objective of this project was to monitor native binding sites of
holocarboxylase synthetase [HCS], a chromatin protein, in human breast cell lines using
an antibody independent technology. This project utilizes the DNA adenine
methyltransferase identification [DamID] technology developed by Dr. Bas van Steensel
from Netherland‟s Cancer Research Institute [1]. Studies conducted in this project verify
the DamID technology in breast cancer and human breast cell lines. The project
eliminates the use of ChIP assays, a commonly used technology to study DNA-protein
interactions and epigenetic mechanisms. ChIP assays depend heavily on specificity of
antibodies and large cell numbers and hence cannot be used to study DNA-protein
interactions in small populations of cells, such as oocytes [2, 3]. The verification of
DamID technology in human breast tissues confirms the principle behind the technology.
Future work with this technology could enable the study of chromatin proteins and
aberrant epigenetic marks in oocytes that are artificially cultured for a period of 2-3 days
prior to in-vitro fertilization.
1.2 Background
1.2.1 Epigenetics

Epigenetics is defined as „the study of heritable changes in gene expression that
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occur independent of changes in the primary DNA sequence‟ [4]. Most of these heritable
changes are established during differentiation and are stably maintained through multiple
cycles of cell division, enabling cells to have distinct identities while containing the same
genetic information. This heritability of gene expression patterns is mediated by
epigenetic modiﬁcations, which include methylation of cytosine bases in DNA, and
posttranslational modiﬁcations, such as methylation, acetylation, ubiquitylation,
phosphorylation, and biotinylation, of histone proteins [5, 6]. The complement of these
modiﬁcations, collectively referred to as the epigenome, provides a mechanism for
cellular diversity by regulating what genetic information can be accessed by cellular
machinery. Failure of the proper maintenance of heritable epigenetic marks can result in
inappropriate activation or inhibition of various signaling pathways and lead to disease
states such as cancer [4, 7].
DNA methylation is perhaps the most extensively studied epigenetic modiﬁcation
in mammalian cell lines [8, 9]. It provides a stable gene silencing mechanism that plays
an important role in regulating gene expression and chromatin architecture, in association
with histone modiﬁcations and other chromatin associated proteins. In mammals, DNA
methylation primarily occurs by the covalent modiﬁcation of cytosine residues in CpG
dinucleotides [8]. CpG islands are preferentially located at the 5‟ end of genes and
occupy 60% of human gene promoters [8]. Methylation of these gene promoters is
generally not detected in normal tissues but hypermethylation of CpG islands resulting in
a loss of gene function is a common feature of almost every type of cancer. CpG gene
promoter is among the most frequently methylated sites in human breast cancer and its
methylation leads to silencing of RASSF1A and several other genes [10]. A screen of
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paired invasive ductal carcinomas with adjacent normal tissues and additional breast
samples obtained from healthy individuals identified several loci that are preferentially
methylated in tumor versus normal tissue; a careful analysis of three such genes
[CYP26A1, KCNAB1, and SNCA] suggests that their methylation in the primary tumors
can be associated with methylation in the adjacent normal tissues [10].
In addition to epigenetic modification of the DNA, the histone N-terminal tails are
crucial to maintaining chromatin stability and they are subject to numerous epigenetic
modifications. Most modifications have some role to play in transcriptional regulation
and so each has the potential to be oncogenic if deregulated deposition leads, for
example, to loss of expression of a tumour suppressor gene [6, 11]. Histone
acetyltransferase [HATs], enzyme responsible for histone acetylation, tend to be
transcriptional activators whereas histone deacetylases [HDACs] tend to be
transcriptional repressors. Many HAT genes are altered in some way in a variety of
cancers [6, 11]. For instance, the p300 HAT gene is mutated in gastrointestinal tumours
[6]. Similarly, methylation of histone proteins has also been associated with various types
of cancer, including lymphoma and gastrointestinal cancer [12]. Lysine
methyltransferases that target histone N-terminal tails contain a so-called SET
domain. This domain possesses lysine methyltransferase activity and numerous SET
domain-containing proteins are implicated in cancer [12, 13]. One example is the Suv39
family of enzymes that catalyse methylation of H3K9. Transgenic mice devoid of these
enzymes are susceptible to cancer, especially B cell lymphomas [13]. Aurora kinases that
perform phosphorylation of histone H3 at serine residues 10, and 28 during mitosis, a
crucial stage of cell cycle, has been linked to pancreatic cancer [11, 13, 14].
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Ubiqutination of histones H2A and H2B at aberrant amino acid site has been assocaited
with lung cancer [15].
1.2.2 Holocarboxylase Synthetase and Biotinylation

A less investigated epigenetic modification of the histone proteins is biotinylation.
There is increasing evidence that histones are covalently modified by the vitamin biotin,
mediated by holocarboxylase synthetase [HCS] and biotinidase [16, 17, 18, 19, 20 ].
Subsequent studies have revealed that HCS is much more important than biotinidase for
biotinylation of histones in vivo [19, 20, 21, 22], with biotinidase demonstrating histone
biotinyl transferase activity in vitro [ 20, 23, 24]. HCS functions as a biotin-ligase for
carboxylases and histones [25]. HCS catalyzes biotinylation of carboxylases and histones
in a two-step ATPdependent reaction [25]. In the first step, biotinyl 5‟-AMP [B-AMP] is
generated; in the second step, biotin is transferred from B-AMP to the lysine residue in
the apocarboxylases and histones [25]. Several histone biotinylation sites have been
identified using recombinant histone biotin ligases, including HCS and synthetic histone
tail peptides. The identified biotinylation sites are lysine (K)-9, K13, K125, K127, and
K129 in histone H2A [26]; K4, K9, K18, and perhaps K23 in histone H3 [20, 24]; and K8
and K12, and perhaps K5 and K16 in histone H4 [22, 23, 24]. The important role of HCS
and subsequent biotinylation of histones has been confirmed in various studies. For
example, phenotypes of HCS knockdown include decreased life span and heat survival in
Drosophila melanogaster [19], and increased transcriptional activity of retrotransposons
in metazoans, predisposing test organisms to chromosomal instability [27]. Biotinylation
of histones has also been shown to play a role in processes such as cell proliferation, gene
silencing, and the cellular response to UV-induced DNA damage [28, 29].
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HCS has a dispersed and distinct distribution in chromatin; however its chromatin
binding sites are poorly defined [19]. Therefore, the objective of this study was to
generate first insights into HCS binding sites in human chromatin of breast cancer and
normal breast epithelial cell lines. It was hypothesized that HCS binding sites of the two
cell lines would be largely similar, as both cell lines are epithelial, with a few variations
due to the genomic abnormality of the cancer cell line. The investigation was carried out
using an antibody independent technology as antibody dependent assays demand
specficity and high cell numbers. Methods that are currently used to study epigenetic
marks will be described in the following section.
1.2.3 Chromatin Immunoprecipitation Assay

The chromatin immunoprecipitation [ChIP] assay is a powerful tool for identifying
proteins, including histone proteins and non-histone proteins, associated with specific
regions of the genome by using antibodies that specifically recognize the protein/s under
investigation. The most common approach taken by researchers to study epigenetic
mechanisms is ChIP assays combined with DNA arrays [7]. ChIP assays together with
DNA arrays have been demonstrated to successfully map epigenetic marks in the entire
genome of various species. This procedure is also an excellent tool to map the enzymes
that mediate epigenetic modifications of DNA and DNA-binding proteins in chromatin.
Briefly, the following steps are commonly involed with ChIP/DNA array method (Fig.
1): [1] DNA and proteins in chromatin are cross-linked using formaldehyde, and
chromatin is sheared to produce fragments of 500–1500 base pairs in size; [2] chromatin
is immunoprecipitated using an antibody that binds the epigenetic mark of interest; the
supernatant does not contain the mark of interest and is discarded; [3] DNA is purified
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from the precipitated chromatin; [4] DNA is chemically labeled [e.g., using fluorophores]
and is hybridized to DNA microarrays; and [5] the epigenetic mark of interest is mapped
in the genome, based on its relative enrichment by antibody precipitation [2]. The
information obtained from the DNA microarray map indicates the relative enrichment of
a given epigenetic mark in a distinct region of the chromatin. This information can then
be correlated to transcriptional activity of genes, such as gene upregulation or
downregulation, and gene silencing, residing in that region.

Figure 1: ChIP assay/DNA microarray Methodology [2]

The combination of ChIP assays and DNA microarrays holds great promise for
the identification of epigenetic modifications and protein involved, but there are also
various challenges associated with this technology that are discussed below. A major
requirement of ChIP assays are antibodies. For each protein or epigenetic mechanism
under investigation there is a need for an antibody specific for the protein or epigenetic
mark of interest. Several common antibodies are commercially available but problem
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arises when the antibodies lack specificity or are not commercially available. In both
situations antibodies have to be synthesized in the lab, which can take anywhere from
two to four months for polyclonal antibodies, and 8-12 months for monoclonal
antibodies. Another drawback with ChIP assays is the requirement for large cell numbers
[in the 106–107 range], which limits the applicability of this assay to rare cell samples,
such as small stem cell batches, oocytes and tissue biopsies that are not available in large
numbers [3]. Aside from the need for specific antibodies and large cell numbers, there is
an ethical issue associated with synthesizing antibodies as they are raised in animals that
are sacrificed at the end of the synthesis process. Finally, a challenge remains with the
lack of appropriate DNA microarrays. The vast majorities of DNA microarrays contain
probes for coding regions in genomes but do not contain probes for noncoding regions.
Noncoding regions contain the majority of regulatory sequences of genes and, hence, are
the prime target for many epigenetic modifications [7].
Therefore, to overcome the problems associated with the ChIP/DNA array
technique, an antibody-independent technology, specifically DNA adenine
methyltransfearse identification [DamID] technology, was used in this study to monitor
HCS in human breast cell lines. This technology would also enable the study of
chromatin proteins in small cell batches as it is independent of cell number.
1.2.4 DNA Adenine Methyltransfearse Identification [DamID] Technology

Prior to the development of the DamID technique, it had been demonstrated that a
DNA cytosine methyltransferase can be targeted in vitro to a pre-determined specific
DNA sequence by tethering it to a DNA-binding protein, such as zinc finger protein [30].
Therefore, it was assessed whether a similar approach could be used to target a
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Escherichia coli DNA adenine methyltransfearse [Dam] to a specific DNA locus in vivo
in Drosophila melanogaster [31]. Dam methylates the N6-position of adenine in the
sequence GATC, which occurs on average every 200–300bp in the fly genome. Dam was
chosen over other methyltransferases essentially because endogenous methylation of
adenines is absent in the DNA of most eukaryotes. When expressed in mammalian cells,
yeast, and Drosophila, Dam has been shown to have no harmful effects on cell viability
or development [31], in contrast to certain cytosine methyltransferases [31]. DamID
technology is based on the creation of a fusion protein consisting of Escherichia coli
DNA adenine methyltransferase [Dam] and a chromatin protein or transcription factor of
interest. Upon expression of the fusion protein in cultured cells or in an intact organism
such as Drosophila, Dam is targeted to the native binding sites of the associated
chromatin protein resulting in local methylation of adenine residues [1, 31]. Hence, the
sequences near a binding site of the protein are marked with a unique methylation tag,
which can be detected using Southern blot-, PCR- and microarray based assays that take
advantage of restriction enzymes that are methylation sensitive [1].
With the development of the DamID technology, it became clear that the entire
human genome could be analyzed for specific DNA-protein interactions and epigenetic
mechanisms using DamID technology in combination with cDNA or oligonucleotide
arrays. DamID technique has a number of advantages over other methods that are
currently used to identify target sequences. First, it eliminates the use of ChIP assays that
call for large cell numbers and heavily depend on the availability and quality of
antibodies. Furthermore, it allows for the detection of protein-DNA interactions as they
occur in living cells unlike ChIP assays that require lysis of cells to obtain chromatin.
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ChIP assays also need crosslinking agents that may induce alterations in the chromatin
structure under investigation leading to identification of unspecific sequences [1, 31]. The
DamID procedure minimizes the detection of non-target sequences as it has been shown
that the technique works best when the Dam fusion protein is expressed at very low
levels, making it unlikely that the fusion protein itself interferes with the functions of the
endogenous protein or its targets.
This study is a proof of principle where feasibility of the DamID technology was
demonstrated in human mammary epithelial cell lines. For this project, Dam was fused
with HCS to map the native binding sites of HCS in human breast and breast cancer cell
genomes in an attempt to identify similarities and differences in the HCS binding regions
between the two cell lines. HCS-Dam fusion plasmid was expressed in the two cell lines
using non-viral gene delivery methods.
1.2.5 Non-Viral Gene Delivery

Gene delivery is the introduction of exogenous DNA or genes into cells for
genetic modification. There are several methods to deliver DNA into cells, including viral
and nonviral techniques [32]. Initial research conducted on gene delivery primarily
focused on using viral carriers, including both retroviruses and adenoviruses, for gene
delivery. Viral vectors exhibited high efficiency at delivering both DNA and RNA to
numerous cell lines [33]. However, fundamental problems associated with viral vector
systems, including toxicity, immunogenicity, and limitations with respect to scale-up
procedures, encouraged the investigation of other potential systems, such as non-viral
gene delivery, to transfer foreign genes into targeted tissue [32].
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Nonviral vector systems, including cationic lipids, polymers, dendrimers, and
peptides, all offer potential ways for compacting DNA for delivery to cells [34].
However, unlike viral analogues that have evolved means to overcome cellular barriers
and immune defense mechanisms, nonviral gene carriers consistently exhibit significantly
reduced transfection efficiency as they are hindered by numerous extra- and intracellular
obstacles. However, biocompatibility and potential for large-scale production make these
compounds increasingly attractive for gene delivery [34]. The most common and
successful nonviral gene delivery method is complexation with a delivery agent, where
negatively charged plasmid DNA is condensed through electrostatic interactions with
cationic lipids to form complexes termed lipoplexes [33, 34] or cationic polymers to form
polyplexes [35, 36]. Complexation provides the DNA protection from degradation by
nucleases and other serum components [32] and enhances cellular uptake by reducing the
effective size of DNA and promoting interactions between positively charged DNA
complexes and the negatively charged cellular membrane [32]. These complexation
agents can also facilitate intracellular trafficking, while dissociating from the DNA to
allow expression [35, 36]. There are two methods in which lipoplexes or polyplexes are
delivered to cells, including the bolus delivery approach and substrate-mediated gene
delivery approach. In the conventional bolus delivery approach, cells are first plated on a
tissue culture substrate and allowed to adhere for a period of 18-20 hours; complexes are
then added and allowed to diffuse through the bulk media to the cells. In the substratemediated gene delivery approach, complexes are first immoblized on a tissue culture
substrate or biomaterial and cells are then seeded on top of the immoblized complexes.
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The latter approach enhances gene transfer as it elevates DNA concentration within cells
local microenvironment [].37
Although the substrate- mediated approach results in enhanced gene transfer,
bolus delivery is commonly used to transfect cells in order to determine transfection
efficiencies. Bolus delivery can report on the ability of a cell line to take up foreign DNA,
and also advises on the need for the substrate-mediated gene delivery approach. If a cell
line is easily transfected using the bolus delivery approach there is usually no need for
transfecting cells via substrate-mediated approach. Substrate mediated approach is
commonly used in studies where higher transfection [>40%] is required or ideal.
For this project, the bolus delivery method was first used to deliver a pEGFP-Luc
reporter gene plasmid complexed with commercially available cationic lipid formations,
Lipofectamine 2000 and FugeneHD, to human breast and breast cancer cells. The DNA
to lipid ratio was optimized, to determine the optimum transfection condition, and
transfection efficiencies were determined. The substrate-mediated approach was not
utilized for the purposes of this project as bolus delivery resulted in transfection
efficiencies suitable for the working of Dam fusion plasmids.
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1.3 Description of Studies

The purpose of this project was to establish the ability of DamID technology, an
antibody independent technique, to monitor chromatin protein binding sites in
mammalian cell lines. This research was conducted in an attempt to eliminate the use of
ChIP assays in studying DNA-protein interactions in mammalian cell lines. HCS, a
nuclear protein known to bind to chromosomes [19], was used as a model protein for this
project. DamID technology was utilized to map the native binding sites of HCS in breast
cancer and normal breast cells. HCS and HCS-Dam plasmids were cloned, breast cells
were then transfected with these plasmids using nonviral delivery techniques, genomic
DNA [gDNA] was isolated, genomic sequences methylated by Dam were digested and
cloned into the pBlueScript II sk(+) cloning vector, which were then further sequenced.
As the cloning approach was utilized for screening the binding sites, only a few sites
were revealed. Future studies should utilize microarray technology, such as cDNA
microarrays, to allow for genome wide analysis of HCS binding sites. Chapter 2
elaborates on purpose, materials/methods, and results of this project. Chapter 3 highlights
the conclusion and future of this project.
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Chapter 2
Identification of holocarboxylase synthetase chromatin binding sites in human mammary
cell lines using the DamID technology

Abstract

Holocarboxylase synthetase (HCS) is a chromatin protein that is essential for
mediating the covalent binding of biotin to histones. Biotinylation of histones plays
crucial roles in the repression of genes and repeats in the human genome. We tested the
feasibility of DNA adenine methyltransferase identification (DamID) technology to map
HCS binding sites in human mammary cell lines. Full-length HCS was fused to Dam for
subsequent transfection into breast cancer (MCF-7) and normal breast (MCF-10A) cells.
HCS docking sites in chromatin were identified by using the unique adenine methylation
sites established by Dam in the fusion construct; docking sites were unambiguously
identified using methylation sensitive digestion, cloning, and sequencing. Fifteen novel
HCS binding sites were identified and included sequences within genes coding for
inositol polyphosphate-5-phosphatase A, corticotropin hormone precursor, myosin heavy
chain 9 non-muscle, cadherins 8 and 11, prolactin, leptin precursor, schwannomin 1,
apoptosis inhibitor, netrin-G1 ligand, neuron navigator, SRY-box4, purinergic receptor,
and CUB and sushi domains. We conclude that DamID is a useful technology to map
HCS binding sites in human chromatin and propose that the entire set of HCS binding
sites could be mapped by combining DamID with microarray technology.
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2.1 Introduction

Holocarboxylase synthetase (HCS) is a chromatin protein [1] that plays a pivotal
role in catalyzing histone biotinylation [1, 2]. Biotinylation is unique as it serves as an
essential metabolic co-factor (biotin) and also functions as a histone modification.
Initially, it was believed that biotinylation of histones is catalyzed by biotinidase [3].
However, subsequent studies revealed that HCS is much more important than biotinidase
for biotinylation of histones in vivo [1, 4, 5, 6, 7], with biotinidase demonstrating histone
biotinyl transferase activity in vitro [4, 8, 9]. Histone biotinylation is a recently
discovered epigenetic mark [10]. Several histone biotinylation sites have been identified
using recombinant histone biotin ligases, including HCS and synthetic histone tail
peptides. The identified biotinylation sites are lysine (K)-9, K13, K125, K127, and K129
in histone H2A [9]; K4, K9, K18, and perhaps K23 in histone H3 [4, 7]; and K8 and K12,
and perhaps K5 and K16 in histone H4 [8, 11, 7]. In vitro biotinylation of K8, K12, and
K16 in histone H4 has been confirmed by mass spectrometric analysis of mammalian
histones [11]. The existence of biotinylated histones was recently questioned [12], but
three independent laboratories [14, 15, 16], in addition to ours [2, 4, 7, 8, 10, 13],
confirmed that biotinylation is a natural histone modification.
Histone biotinylation is a comparably rare event (<0.1% of histones are
biotinylated) [10, 14], but the abundance of an epigenetic mark is no marker for its
importance. For example, only ~3% of cytosines are methylated, but the role of DNA
methylation in gene regulation is undisputed [17]. Likewise, serine-14 phosphorylation in
histone H2B and histone poly(ADP-ribosylation) are detectable only after induction of
apoptosis and major DNA damage, respectively, but the role of these epigenetic marks in

30

cell death is unambiguous [18, 19, 20]. Moreover, low abundance of an epigenetic mark
in bulk histone extracts compared with its high enrichment at specific loci is consistent
with regulatory function. Evidence suggests that about one out of three histone H4
molecules are biotinylated at K12 in telomeric repeats [21]. K12-biotinylated histone H4
(H4K12bio), K9-biotinylated H3 (H3K9bio), and K18-biotinylated H3 (H3K18bio) are
enriched at transcriptionally repressed loci in mammalian genomes, suggesting a role for
histone biotinylation in gene regulation [5, 6, 13, 22]. The important role of HCS and
subsequent biotinylation of histones has been confirmed in various studies. For example,
phenotypes of HCS knockdown include decreased life span and heat survival in
Drosophila melanogaster [1], and increased transcriptional activity of retrotransposons in
metazoans, predisposing test organisms to chromosomal instability [6].
HCS has a dispersed and distinct distribution in chromatin, however its chromatin
binding sites are poorly defined [1]. Therefore, the objective of this study was to adopt
DNA adenine methyl transferase identification (DamID) technology [23] to generate first
insights into HCS binding sites in human chromatin, and to pave the way for more
comprehensive mapping efforts in future studies. Briefly, DamID technology is based on
fusing DNA adenine methyltransferase (Dam) from Escherichia coli to a chromatin
protein or transcription factor of interest [23], e.g., HCS. Upon expression of the fusion
protein in cultured cells or in an intact organism such as Drosophila, HCS guides Dam to
HCS binding sites, where Dam creates a unique adenine methylation tag, which is absent
in most eukaryotes. Adenine methylation sites can be identified by methylation sensitive
sequencing procedures.
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In this proof-of-concept study, DamID technology was used to map, for the first
time, genomic HCS- binding sites in the human chromatin using mammary epithelial cell
lines, human breast (MCF-10A) and breast cancer (MCF-7), as aberrant epigenetic marks
have already been shown in breast cancer cells [24].
2.2 Materials and Methods

2.2.1 Cloning HCS-Dam fusion plasmid
The pIND (V5) EcoDam [23, 25] vector was obtained from Dr. Bas van Steensel‟s
laboratory at the Netherlands Cancer Institute. pIND (V5) EcoDam codes for E.coli Dam,
and contains a multiple cloning site upstream of the Dam open reading frame. An HCSDam fusion construct was generated as follows. Full-length human HCS was PCRamplified using HCS-pET41a as a template [2], AccuPrime™ Pfx DNA polymerase
SuperMix (Invitrogen, Carlsbad, CA) and the following primers: 5‟GTTCGAATTCATGGAAGATAGACTCCACATGG-3‟ (forward, EcoRI site
underlined) and 5‟-GTTTCTCGAGCCGCCGTTTGGGGAGGATGAGG-3‟ (reverse,
XhoI site underlined). Following amplification, HCS and pIND (V5) EcoDam vector
were digested with EcoRI and XhoI (Fermentas, Glen Burnie, MD), ligated using FastLink™ DNA Ligation Kit (Epicenter Biotechnologies, Madison, WI), and transformed
into MAX Efficiency® DH5α™ Competent Cells (Invitrogen). The HCS-Dam fusion
plasmid was sequenced (Eurofin MWG Operon, Huntsville, AL) to confirm its identity
and was denoted “HCS-Dam.” Two control plasmids were used in HCS mapping studies.
(i) Plasmid pIND V5 EcoDam [23], codes for Dam only and was used to identify
artifactual binding of Dam to chromatin that was not mediated by HCS. (ii) Plasmid
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“HCS” codes for full-length human HCS and was used to identify artifactual adenine
methylation in the absence of Dam. Plasmid HCS was generated as described above for
HCS-Dam, but the following reverse primer was substituted for the original reverse
primer: 5‟GTTTTCTAGATTACCGCCGTTTGGGGAGGATGAGG-3‟ (reverse; XbaI
site underlined). The stop codon in this reverse primer terminates translation after the
HCS open reading frame.
2.2.2 Cell culture

MCF-7 and MCF-10A cells (ATCC, Manassas, VA) were used for all studies. MCF-7
cells were cultured in DMEM/F12 media (ATCC) with the following supplements (v/v):
1% L-glutamine (Invitrogen), 10% fetal bovine serum (Invitrogen), 1%
antibiotic/antimycotic (Invitrogen), 1% nonessential amino acids (Invitrogen), and 0.06%
bovine insulin (Sigma-Aldrich, St. Louis, MO). MCF-10A cells were cultured in
mammary epithelial growth media (MEGM) + bullet kit (Lonza, Basel, Switzerland), 1%
(v/v) fetal bovine serum, and 0.05% (v/v) cholera toxin (Sigma-Aldrich).
2.2.3 Transfection Optimization using Reporter gene pEGFP-Luc

Transfection was optimized using a plasmid containing reporter genes, pEGFP-Luc
(Clonetech, Mountain View, CA) in MCF-7 and MCF10A cell lines. pEGFP-Luc
encodes for a fusion of enhanced green fluorescent protein (EGFP) and luciferase (Luc)
from the firefly Photinus pyralis. Briefly, 20,000 cells/well were seeded in a 48-well
plate and cells were allowed to adhere for 18 hours. After 18 h, cells were transfected
with pEGFP-LUC-transfection reagent complexes formulated in serum-free opti-MEM
media (Invitrogen). For MCF-7 cells, pEGFP-Luc was complexed with Lipofectamine
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(LF) 2000 (Invitrogen,) and the complexes were incubated for 20 min. For MCF10A
cells, pEGFP-Luc was complexed with FugeneHD (Roche, Madison, WI) and the
complexes were allowed to incubate for 15 minutes. After incubation, complexes were
delivered to the two cell lines. Cells were assayed for EGFP expression using
fluoroescence microscopy (Leica DMI 3000B, Bannockburn, IL) at 24 and 48 h posttransfection. At 48 h, cells were lysed and cell lysate was assayed for luciferase
expression, using the Luciferase Assay System (Promega, Madison, WI) and a
luminometer (Turner Biossytem, Sunnyvale, CA), which returned luciferase activity in
RLUs (Relative Light Units). Luciferase activity was normalized to the total protein
amount, in the cell lysate, determined with the BCA protein assay (Pierce, Rockford, IL)
and transfection levels were reported as RLUs/mg of protein. Each transfection
experiment was performed in duplicate.
DNA (pEGFP-Luc) amount and DNA to transfection reagent ratio was varied to
determine an optimum transfection condition for both cell types. Conditions were
optimized based on the following factors i) transfection efficiency (percentage of EGFPpositive cells assayed by fluorescence microscopy); ii) gene activity (RLUs/mg of
protein); and iii) cell viability and morphology (analyzed through phase microscopy
using Leica DMI 3000B).
2.2.4 Transfection of cells with HCS-Dam and control plasmids
For transfection with HCS-Dam, EcoDam and HCS plasmids, 3.5 x 106 cells were
seeded in T-75 flasks and allowed to adhere for 18 h, after which time cells were
transfected with one of the three plasmids as follows. DNA was complexed with
Lipofectamine (LF) 2000 (Invitrogen) or FugeneHD (Roche) in serum-free opti-MEM
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media (Invitrogen). For MCF-7 cells, 6.75 µg of each plasmid was complexed with 10.2
µl of LF 2000 in a 1:1.5 DNA to lipid ratio (µg of DNA to µl of LF2000). These
complexes were allowed to incubate for 20 min and were then added to each designated
flask. For MCF-10A cells, 8.25 µg of each plasmid was complexed with 20.625 µl of
FugeneHD in a 1:2.5 DNA to Fugene ratio (µg of DNA to µl of FugeneHD). These
complexes were incubated for 15 min and were then delivered to each designated flask.
Forty-eight hours after transfection, cells were collected and lysed using protocols
specific for isolation of RNA or genomic DNA.
2.2.5 Quantitative Real-time PCR (qRT-PCR)

Total RNA was collected using the RNeasy mini kit (Qiagen, Valencia, CA) and
reverse transcribed using the ImProm-II Reverse Transcription System (Promega). The
cDNA was used to confirm successful transfection of cells with plasmids HCS-Dam,
EcoDam, and HCS, using the following primers and SYBR green (Qiagen) in qRT-PCR
expression analysis: (i) HCS-Dam = 5‟-GCAACTCCTTCGACATGCTGAGAAA-3‟
(forward, positioned in HCS region) and 5‟-TCTTCATGCCGGTACGCGTAGAAT-3‟
(reverse, positioned in Dam region); (ii) Dam = 5‟TCTGGTTGAGCGCCATATTCCAGT-3‟ (forward) and 5‟TGTACAAAGCCAGCAGTTCGTCCA-3‟ (reverse); and (iii) HCS = 5‟ATGGAAGATAGACTCCACAT-3‟ (forward) and 5‟TGAGACCTGATCCTTAACTTCC-3‟ (reverse). Glyceraldehyde 3-phosphate
dehydrogenase was used as the reference gene for qRT-PCR normalization, using primers
5‟-TCCACTGGCGTCTTCACC-3‟ (forward) and 5‟-GGCAGAGATGATGACCCTTT-
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3‟ (reverse) [6]. The cycle threshold values were used to calculate amplicon abundance
[31].
2.2.6 Mapping HCS-binding sites of adenine-methylated Sequences

Genomic DNA was purified 48 h after transfection by using the DNeasy mini kit
(Qiagen). DNA was digested with DpnI (Fermentas, Glen Burnie, MD), which is
sensitive to adenine methylation. The digested fragments were purified using a PCR
purification kit (Qiagen) and ligated into the pBlueScript II sk(+) vector after
linearization with BamHI (Fermentas); the Fast-Link™ DNA Ligation Kit was used for
ligation. Note that digestion with DpnI and BamHI produces compatible overlaps. The
ligation mixture was transformed into MAX Efficiency® DH5α™ Competent Cells and
the cells were plated on LB-Ampicillin plates. White colonies were randomly selected for
sequencing by using the T7 promoter primer (Eurofins MWG Operon, Huntsville, AL).
2.2.7 Statistics

The GraphPad Prism 5.0 program (La Jolla, CA) was used to plot transfection
optimization and qRT-PCR graphs. Data are presented as the mean ± SEM. Multiple
comparisons were evaluated by one-way ANOVA, followed by post hoc Tukey test.
Values were considered statistically significant if P < 0.05.

2.3. Results and Discussion

2.3.1 Transfection Optimization
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Work in Drosophila [26] suggests that it is important to keep the expression level
of Dam-fusion proteins very low to avoid saturating methylation levels [23]. The pIND
(V5) EcoDam vector consists of an inducible promoter; however it has been shown that
leaky expression of Dam fusion plasmids is sufficient for specific methylation of target
sequences [26, 27]. Induction of the vector leads to high background methylation, which
makes the identification of target sequences difficult [27]. Ideally a transfection
efficiency of 30% or higher is needed for transient transfection with Dam fusion proteins
[27], although good binding maps have also been obtained with lower efficiency
transfections [27]. Transfection was hence optimized using pEGFP-Luc reporter plasmid
in the two breast cell lines in order to determine the maximum transfection or expression
level that could be achieved with adequate cell viability. It was found that 0.11 µg of
pEGFP-Luc in a 1:1.5 DNA: LF2000 ratio was the optimum transfection condition for
MCF-7 cells. This condition resulted in 16 ± 3.5 % transfection efficiency (Fig. 2A) and
a luciferase activity of 3× 109 RLUs/mg of protein (Fig. 2B). Similarly, for MCF-10A
cells, 0.11 µg of pEGFP-Luc using 1:2.5 DNA to FugeneHD ratio was determined to be
the optimum condition. This condition resulted in 29 ± 2.4% transfection efficiency (Fig.
3A) and a luciferase activity of 4× 109 RLUs/mg of protein (Fig. 3B). The optimal
conditions were then used for the DamID experiments. Although, transfection efficiency
was less than the desired 30% for MCF-7 cells, expression of Dam plasmids were
confirmed, in vitro, using qRT-PCR (results discussed below), prior to the conduction of
the DamID assay.

37

5.010 09

c
c

15

b
10
5

4.010 09

c

3.010 09
2.010 09

b

1.010 09

a

d

B

a

a

b

a
a
0.
15
ug

0.
11
ug

0.
10
ug

0.
09
ug

0.
05
ug

co
nt
ro
l

0.
15
ug

0.
11
ug

0.
09
ug

0.
05
ug

0.
07
ug

0.0

0

co
nt
ro
l

A
20

Rlu/mg of protein

Avg. Transfection Efficiency%

25

pEGFP-Luc Amount

pEGFP-Luc Amount

Figure 2. Complex conditions (DNA to transfection reagent ratio and DNA amount) used
for transfection in MCF-7 cells used for DamID assays were selected based on
optimization of transfection conditions in which ratio and DNA amounts were compared
to transfection efficiency (percentage of EGFP-positive cells) (A) and luciferase gene
activity (B). This figure represents an optimum ratio of 1:1.5 DNA: LF 2000 at different
pEGFP-Luc concentrations. Each bar represents the mean + SEM, n = 2. a,b,c, dBars with
different letters indicate significant differences (P < 0.05) between treatments.
6.010 09

B

c

a, b

b, c

20

a, d
d, e

10

b

4.010 09

a

a, b

a
a

2.010 09

d, e

c

e

1.
00
ug

0.
25
ug

0.
15
ug

0.
11
ug

0.
10
ug

co
nt
ro
l

1.
00
ug

0.
25
ug

0.
15
ug

0.
11
ug

0.
10
ug

0.
07
ug

pEGFP-Luc Amount

0.
07
ug

0.0

0

c
co
nt
ro
l

A
30

Rlu/mg of protein

Avg. Transfection Efficiency%

40

pEGFP-Luc Amount

Figure 3. Complex conditions (DNA to transfection reagent ratio and DNA amount) used
for transfection in MCF-10A cells used for DamID assays were selected based on
optimization of transfection conditions in which ratio and DNA amounts were compared
to transfection efficiency (percentage of EGFP-positive cells) (A) and luciferase gene
activity (B). This figure represents an optimum ratio of 1:2.5 DNA: Fugene at different
pEGFP-Luc concentrations. Each bar represents the mean + SEM, n = 2. a,b,cBars with
different letters indicate significant differences (P < 0.05) between treatments.

38

2.3.2 Plasmid expression

Transfection of mammary cells with plasmids Dam-HCS, EcoDam, or HCS
produced the expected expression patterns compared with non-transfected control cells.
When cDNA was analyzed using PCR primers for HCS, the transcript abundance was
170-fold and 62-fold greater in MCF-7 cells transfected with HCS and HCS-Dam,
respectively, than in non-transfected control cells (Fig. 4A); the abundance of HCS
transcript was not altered by transfection with EcoDam (negative control) as it did not
contain HCS. When cDNA was analyzed using PCR primers for the HCS-Dam fusion
protein, the transcript abundance was 2000-fold greater in MCF-7 cells transfected with
HCS-Dam than in non-transfected control cells (Fig. 4B); the abundance of HCS-Dam
fusion transcript was not altered by transfection with EcoDam and HCS (negative
controls) as these controls lacked HCS-Dam fusion. When cDNA was analyzed using
PCR primers for Dam, the transcript abundance was 660-fold and 800-fold greater in
MCF-7 cells transfected with EcoDam and HCS-Dam, respectively, than in nontransfected control cells (Fig. 4C); the abundance of Dam transcript was not altered by
transfection with HCS (negative control) as it did not contain Dam. Results were
comparable in MCF-10A cells (Fig. 5).
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2.3.3 HCS-docking sites

Following the validation of expression of fusion and control plasmids, these
plasmids were expressed in MCF-7 and MCF-10A cell lines, genomic sequences
methylated by Dam were cloned into the pBlueScript II sk(+) cloning vector, positive
clones were obtained and sequenced. When five clones from HCS-Dam positive MCF-7
cells were annotated by NCBI‟s basic local alignment search tool (BLAST), seven unique
HCS-binding sequences, within specific genes, were detected (Table 1). Each clone
returned more than one sequence, because of the complimentary ends created during
digestion with DpnI and the random ligation of these fragments during ligation and
cloning. Transfection with plasmid HCS (negative control) did not produce any clones in
MCF-7 cells. We conclude that HCS greatly enhances the binding of Dam at distinct
genomic loci. Results in MCF-10A cells were comparable to those in MCF-7. Five clones
from HCS-Dam positive MCF-10A cells detected eight unique sequences when annoted
by BLAST, (Table 2).
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Table 1
Genomic HCS binding sites in MCF-7 cells.
MCF-7
HCS-Binding Loci

Genes

Chromosome

5‟CCACAGAATCAGGGGATAACG
CAGGAAAGAACAT- 3‟

Inositol
polyphosphate-5phosphatase A

10

5‟CAGGAAAGAACATGTGAGCAA
AAG- 3‟

Corticotropin
releasing hormone
precursor (CRH),
and
Homolog of yeast
ribosome biogenesis
regulatory protein
(RRS1)

8

5‟Cadherin 8 and,
16
ATAGCTCACGCTGTAGGTATCT Cadherin 11
CAGTTCGGTGTA- 3‟
Type2 preproproteins

GenBank
Acession
Number
NM_00553
9.3

NM_0007
56.2
NM_0151
69.3

NM_0017
96.2
NM_0017
97.2

5‟ACCATGCTCTTTCCCCCTTGCA
ACCTCACTCATTCTCTCTCCTA
TTC- 3‟
5‟GGTTTTTATCTTTGCAAGCAGC
AGAT-3‟

Schwannomin
interacting protein 1
(SCHIP1)

3

NM_0145
75.2

Neuron navigator 3
(NAV3)

12

NM_0149
03.4

5‟-

Leptin precursor

7

NM_0002
30.2

5‟AAAGGGATTTTGGGGCATGAG
ATCATC- 3‟

Apoptosis inhibitor 5
isoform b

11

NM_0065
95.3

5‟AAAGGGATTTTGGGGCATGAG
ATCATC- 3‟

Netrin-G1 ligand

11

NM_0209
29.1

ATTCCACACAACATACGAGC-3‟
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Table 2
Genomic HCS binding sites in MCF-10A cells.
MCF-10A
HCS-Binding Loci

Genes

Chromosome

5‟CCACAGAATCAGGGGATAACG
CAGGAAAGAACAT- 3‟

Inositol
polyphosphate-5phosphatase A

10

5‟TCGCCCTATAGTGAGTCGTAT3‟

Homo sapiens
myosin, heavy chain
9, non-muscle
(MYH9)

22

NM_0024
73.4

5‟CAGGAAAGAACATGTGAGCAA
AAG- 3‟

Corticotropin
releasing hormone
precursor
(CRH), and
Homolog of yeast
ribosome biogenesis
regulatory protein
(RRS1)

8

NM_0007
56.2
NM_0151
69.3

5‟SRY (sex
TGAGCTAACTCACATTAATTGC determining region
GTTG- 3‟
Y)-box 4, and
Prolactin

6

NM_0031
07.2
NM_0011
63558.1

5‟CCTGTTTTGCAGGGTGCTTT- 3‟

Purinergic receptor
P2X5 isoform A and
B

17

NM_0025
61.2

5‟GAGCTCCAGCTTTTTTTCTCTT
TAG- 3‟

Tetratricopeptide
repeat domain 7B

14

XM_5101
18.2

5‟CCTGGGGTGCCTAATGAGTG3‟

CUB and Sushi
multiple domains 1

8

Q96PZ7-1

5‟ATTCCACACAACATACGAGC3‟

Leptin precursor

7

NM_0002
30.2

GenBank
Acession
Number
NM_00553
9.3
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Please also note the following observations. First, when MCF-10A cells were
transfected with plasmid HCS, one clone with one single sequence was identified
compared with the seven clones in cells transfected with HCS-Dam, indicating that the
false positive rate due to these artifacts might be up to 14% in Dam-based assays.
Second, for the MCF-10A cell line, a locus within X-linked neuroligin4 gene was
disregarded as a potential HCS docking site, as it appeared due to artefactual methylation
by pIND (V5) EcoDam control. No such artifactual methylation by Dam was observed
for MCF-7 cells. Third, four HCS-docking sites were found to be common between
MCF-7 and MCF-10A cells, indicating a 28% overlap in the HCS binding regions
identified in the two epithelial cell lines, further increasing confidence that the results
produced by HCS-Dam technology are real. Note that clones were selected randomly in
this proof-of-concept study and, therefore, one must not expect a 100% overlap in clones.
Comprehensive maps can only be generated by using microarray-based technologies or
high-throughput sequencing and may show an expected overlap of 100% between the
identified genes, as both cell lines used in this study are of epithelial origin or
alternatively could allow for determination of non-overlapping loci specific for either cell
type. Also note that the following gene sets share a common HCS-docking locus: CRH
and RRS1 (Tables 1 and 2), cadherin 8 and cadherin 11 (Table 1) and, SRY-box4 and
prolactin (Table 2).
The overlapping HCS binding regions were found within four genes: INPP5A on
chromosome 10, and CRH and RRS1 on chromosome 8, and leptin precursor on
chromosome 7. INPP5A is a member of the INPP enzyme family [28, 29]. INPPs
regulate diverse cellular processes such as protein trafficking, phagocytosis, and synaptic
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vesicle recycling [29]. Loss of genetic material in the chromosome that includes INPP5A
has been associated with brain tumors and leukemia [30]. It has also been demonstrated
that loss or lower expression of INPP5 is an early mechanism in the development of
cutaneous squamous cell carcinoma [30]. Similarly, CRH is a polypeptide hormone and
is involved in stress response [31]. CRH has been implicated in various stress-induced
abnormalities, including changes in both human and rat gastrointestinal functions such as
motility and gastric acid secretion [31]. CRH gene has been shown to be highly expressed
in MCF-7 cells [32], thus providing the basis to postulate a mechanism according to
which CRH is secreted by tumor cells and exerts local – paracrine or autocrine –
inhibitory action over breast cell growth [32]. Also, on chromsome 8, a locus of ribosome
biogenesis regulatory protein (RRS1) was determined to be HCS-docking site in the two
breast cell lines. RRS1 has been shown to regulate ribosome biosynthesis pathway in
growing cells [33]. Leptin precursor gene, on chromosome 7, is known to be an integral
component of a physiological signalling system that regulates fuel stores and energy
balance in specific areas of the brain [34].The finding that INPP5A, CRH, RRS1, and
leptin precursor genes possess potential HCS binding sites in human breast tissues
underlines their importance in the interactions with the chromatin that further lead to
biotinylation of histone proteins.
This study proves feasibility of the DamID technology to identify, for the first
time, potential HCS binding sites in human mammary epithelial cell lines. DamID
technology eliminates the need for large cell numbers and antibodies and thus represents
a viable alternative method to the chromatin immunoprecipitation (ChIP) assay, a
frequently used tool to investigate DNA-chromatin interactions. With the establishment
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of the abilty of DamID technology to identify chromatin protein binding sites, the future
goal of this project is to use the technology along with cDNA microarray sequencing to
monitor chromatin proteins in small cell samples, such as oocytes. While the combination
of techniques employed in this study only provided a snapshot of events occurring at the
genomic level, it proves the DamID technology‟s utility and when combined with
microarray sequencing, has the potential for full genome analysis.
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Chapter 3
Conclusions and Future Goals
3.1 Introduction

Studies conducted in this project verified the DNA adenine methyl transferase
identification (DamID) technology in human breast (MCF-10A) and breast cancer (MCF7) cell lines (Chapter 2). The technology was successfully used to map the binding sites
of holocarboxylase synthetase (HCS) chromatin protein in MCF-7 and MCF-10A cells.
Fifteen novel HCS binding sites were identified and included sequences within genes
coding for inositol polyphosphate-5-phosphatase A, corticotropin hormone precursor,
myosin heavy chain 9 non-muscle, cadherins 8 and 11, prolactin, and several others.
While it was shown in this study that DamID technology can be employed to investigate
chromatin proteins in human breast tissues, the future goal of this project is to study
chromatin proteins and epigenetic marks in oocytes that are artificially cultured for the
purpose of assisted reproductive technology (ART). DamID was established in this
project because more traditional and commonly used chromatin immunoprecipitation
(ChIP) assays require large cell numbers (typically in the 106–107 range) and highly
specific antibodies [1, 2]. ChIP assays, therefore, cannot be utilized for studying
chromatin in oocytes as they are hard to obtain in large batches. In addition, DamID
technology has several other advantages over ChIP assays. It eliminates the need for
target-specific antibodies making the investigation of any chromatin protein, such as
DNA methyltransferases and histone acetyltransferases, relatively easy. Unlike ChIP
assays, DamID technology also allows for the detection of protein-DNA interactions as
they occur in living cells and does not require cell lysis to acquire the chromatin [3]. As
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opposed to the DamID technology, ChIP assays also require crosslinking agents that can
induce alterations in the chromatin structure under investigation leading to the
identification of unspecific-target sequences [3].
3.2 Assisted Reproductive Technology (ART) and Birth Defects

According to 1992 Fertility Clinic Success Rate and Certification Act, ART is
defined as fertility treatments in which both eggs or oocytes and sperms are handled in
the laboratory [4]. Although the use of ART has become a widely accepted and
implemented therapy for some forms of infertility, there have been concerns about the
long-term safety of removing and handling germline cells [4]. Studies conducted between
the years 1991-1998 demonstrate a correlation between ART and low birth weight
(LBW) and multiple births [5, 6, 7]. Since low birth weight is in part epigenetically
controlled, an epigenetic connection seems plausible for birth defects in ART population
[4].
Several human disorders involving birth defects have now been shown to be
caused by epigenetic alterations. The cardinal features of Beckwith-Wiedemann
syndrome (BWS), which is linked to a cluster of imprinted genes on chromosme 11p15.5,
are prenatal overgrowth, abdominal wall defects, neonatal hypoglycemia, and
macroglossia [4]. Prader-Willi syndrome, which is linked to a cluster of imprinted genes
on chromosome 15p11-13 normally expressed from the paternal allele, is characterized
by muscular hypotonia, obesity, mental retardation, and hypogonadotrophic
hypogonadism. Another neurological birth defect syndrome, Angelman syndrome (AS),
is also linked to chromosome 15p11-13; in this case, to a gene normally expressed from
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the maternal allele. The characteristic features of AS include severe developmental delay,
absent speech, seizures, ataxia, hyperreﬂexia, and hypotonia [4]. Genetic mutations of the
epigenetic machinery also cause birth defects. Rett syndrome is caused by mutations in
the X-linked gene encoding MeCP2, a methyl-CpG-binding protein [4].
The cause of the link between ARTs and epigenetic alterations is currently
unknown. It could be due to some aspect of the ARTs techqniue. There is a wide range of
different ARTs, such as in vitro fertilization, which are now routinely used within clinics.
Techniques utilized for ART, duration of artificial culture, and mechanical manipulation
can expose one or both of the germ cells to an altered hormonal regime [8]. Any
alterations to the normal environment of the oocyte or sperm could result in changes to
some aspect of their imprinting mechanisms [8]. For example, studies in humans and
mice suggest that superovulation can lead to the production of oocytes without their
correct primary imprint, and aberrant DNA methylation [9]. It is unclear whether the
cause is hormonal stimulation, gamete manipulation, or culture conditions [8]. It has been
suggested that in vitro culture of gametes, zygotes, and embryos, representing a common
feature of all ART techniques, results in an accumulation of epigenetic alterations leading
to an enhancement in fetal growth and heavier newborn cattle, known as large offspring
syndrome [8].
Evidences mentioned above suggest a link between artificial culture of oocytes,
used in ART, and aberrant epigenetics and birth defects. Therefore the future goal of this
project is to establish biotinylation marks in artificially manipulated mice oocytes, before
proceeding on to human oocytes. Biotinylation is a recently discovered epigenetic mark
and is mediated by HCS chromatin protein [10]. Genomic binding sites of HCS would be
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mapped in artificially cultured oocytes, using the DamID technology. This work would
lay the foundation for succeeding studies where the aberrancy and normalcy of
biotinylation marks in cultured oocytes, prior to fertilization, would be investigated.
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